Physiology-stratified analysis of ORBITA

May 22, 2018, European Society of Cardiology

Invasive physiology data from 196 patients from the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial were used to assess the fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) predictors of placebo-controlled efficacy of percutaneous coronary intervention (PCI) in stable coronary artery disease. Patients enrolled had stable angina and single vessel coronary artery disease. At pre-randomisation the majority had Canadian Cardiovascular Society class II or III symptoms (150/196, 76.5 percent). Mean FFR and iFR were 0.69±0.16 and 0.76±0.22, respectively. 97 percent of patients had one or more positive non-invasive or invasive tests for ischaemia.

"In particular, from this study, we've seen that the degree of ischaemia on iFR and FFR entirely predicts the degree of improvement in ischaemia that's seen on dobutamine stress echo. What this means for physicians is that we will be able to use the iFR and FFR data before an intervention to predict exactly how much improvement in ischaemia we can expect for our patients following successful stenting. This is the first placebo-controlled evidence we have had of this kind," says Rasha Al-Lamee, Interventional Cardiology Consultant and Principal Investigator, ORBITA.

FFR and iFR was performed solely for this research question, and so the Interventionalist in the catheterisation laboratory was blinded to the results. Assessment of response variables, treadmill exercise time, stress echo score, symptom frequency, and angina severity were performed at pre-randomisation and blinded follow-up. Effects were calculated by analysis of covariance. The ability of FFR and iFR to predict placebo-controlled changes in response variables was tested using regression modelling.

The placebo-controlled effect of PCI was more clearly seen by stress echo score and freedom from angina than change in treadmill exercise time. The estimated effect of PCI on between-arm pre-randomisation-adjusted total exercise time was 20.7s (95 percent CI: -4.0 to 45.5; p=0.100) with no dependence on FFR (pinteraction=0.318) and iFR (pinteraction=0.523). PCI improved stress echo score more than placebo (1.07 segment units, 95 percent CI: 0.70 to 1.44, p less than than 0.00001). The placebo-controlled effect of PCI on stress echo score increased progressively with decreasing FFR (pinteraction<0.00001) and decreasing iFR (pinteraction less than 0.00001). PCI resulted in more patient-reported freedom from angina than placebo (49.5 percent versus 31.5 percent; OR 2.47, 95 percent CI: 1.30 to 4.72; p=0.006) but neither FFR (pinteraction=0.693) nor iFR (pinteraction=0.761) modified this effect.

This report of ORBITA stratified by invasive haemodynamic measures of stenosis severity provides the first placebo-controlled evidence of the association between FFR and iFR and the magnitude of benefit attributable to PCI.

Dr. Al-Lamee went on to say that "this is the first placebo-controlled trial looking at how invasive physiology predicts the efficacy of PCI. In this publication and in the primary publication in The Lancet we saw that angioplasty improved ischaemia as assessed by dobutamine stress echo. However, in this analysis we were also able to assess an additional secondary endpoint of freedom from angina. What is most interesting is that we found that angioplasty increased the number of patients who were free of angina by 20 absolute percentage points. For physicians, this means that one in 5 patients that we treat with angioplasty vs. placebo will be more likely to be free from angina. For our patients, this is one of the most important things we can tell them, that they are more likely to become symptom free."

"The next step for ORBITA is to look at the degree to which stress echo itself predicts the placebo-controlled impact of PCI", Rasha Al-Lamee concluded. "In order to build on some of the questions answered in ORBITA as well as being able to apply ORBITA to a wider patient base, we are also preparing for ORBITA 2 which will be a larger trial, with wider inclusion criteria for patients with stable angina".

The study's main findings are:

  • PCI improves ischaemia as assessed by dobutamine stress echocardiography.
  • Per 100 patients treated, PCI delivers freedom from angina in ~20 more patients than placebo (Number Needed to Treat = 5).
  • FFR and iFR predict the placebo-controlled PCI effect on stress echocardiography.
  • FFR and iFR did not predict the placebo-controlled PCI effect on symptoms or treadmill exercise time.

The main clinical implications are:

  • PCI renders more patients free of angina than does placebo.
  • FFR and iFR do predict the strength of the PCI effect on ischaemia, but this is only clearly seen on blinded evaluation. It is not visible in the symptom scores or exercise times.

Explore further: Study of heart stents for stable angina highlights potential of placebo effect

Related Stories

Study of heart stents for stable angina highlights potential of placebo effect

November 2, 2017
Coronary artery stents are lifesaving for heart attack patients, but new research suggests that the placebo effect may be larger than previously thought.

SCAI examines strengths and weaknesses of sham PCI trial

November 2, 2017
This year, the Society for Cardiovascular Angiography and Interventions (SCAI) celebrated the forty-year anniversary of a groundbreaking procedure, now known as percutaneous coronary intervention (PCI), that has saved millions ...

Ivabradine improves angina-related quality of life

December 23, 2015
(HealthDay)—For patients with angina pectoris, ivabradine is associated with improvements in certain parameters of quality of life (QoL), according to a study published online Dec. 22 in Circulation: Cardiovascular Quality ...

Coronary artery spasms rare during dobutamine stress echo

March 9, 2012
(HealthDay) -- The occurrence of coronary artery spasm (CAS) during dobutamine stress echocardiography (DSE) is rare, with a prevalence of 0.4 percent, according to a study published in the March 15 issue of The American ...

Cardiac shock wave therapy improves angina symptoms

March 30, 2012
(HealthDay) -- Cardiac shock wave therapy (CSWT) can significantly improve symptoms, ischemic threshold during exercise, and specific quality-of-life parameters for patients with chronic refractory angina pectoris, according ...

First European randomized trial of PCI vs. optimized medical therapy in CTO

May 18, 2017
Revascularization with percutaneous coronary intervention (PCI) achieves a high success rate with low procedural risk in patients with coronary chronic total occlusion, show results reported at EuroPCR 2017 from the first ...

Recommended for you

New cellular pathway helps explain how inflammation leads to artery disease

June 21, 2018
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis—deposits of cholesterol, fats and other substances that create plaque, clog arteries and ...

'Smart stent' detects narrowing of arteries

June 19, 2018
For every three individuals who have had a stent implanted to keep clogged arteries open and prevent a heart attack, at least one will experience restenosis—the renewed narrowing of the artery due to plaque buildup or scarring—which ...

Marriage may protect against heart disease / stroke and associated risk of death

June 18, 2018
Marriage may protect against the development of heart disease/stroke as well as influencing who is more likely to die of it, suggests a pooled analysis of the available data, published online in the journal Heart.

Deaths from cardiac arrest are misclassified, overestimated

June 18, 2018
Forty percent of deaths attributed to cardiac arrest are not sudden or unexpected, and nearly half of the remainder are not arrhythmic—the only situation in which CPR and defibrillators are effective—according to an analysis ...

Tick-borne meat sensitivity linked to heart disease

June 15, 2018
University of Virginia School of Medicine researchers have linked sensitivity to an allergen in red meat—a sensitivity spread by tick bites—with a buildup of fatty plaque in the arteries of the heart. This buildup may ...

The molecules that energize babies' hearts

June 14, 2018
A metabolic process that provides heart muscle with energy fails to mature in newborns with thickened heart walls, according to a Japan–Canada research team.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.